Healthcare economic benefits

pricing

 

The Swedish Institute for Health Economics has performed a Health Economic Study for the early detection of pancreatic cancer. This study has been published in International Journal of cancer and in summary shows that the possibility to screen high risk patients for pancreatic cancer, using the Immunovia serum biomarker signature test IMMray™ PanCan-d, result in a cost for a QALY (Quality Adjusted Life Year) that is well below the willingness to pay threshold in Europe.

The graph above illustrate the cost per QALY for different screening groups. Wilingness to pay per QALY is a threshold where the payers of the health systems in Europe consider it health economically sound to introduce a new tool. The willingness to pay vary between countries and the red line at 50kEUR illustrate an average willingness to pay per QALY in Europe. Therefore if the cost per QALY is below this line the test would be considered health economically justified to introduce.

The first bar is the result of screening all of the population over 60 which, as expected, is not health economically justifiable due to the low incidence rate. The second bar is for the risk group of middle aged newly onset of diabetes and the third for a hereditary risk group, both showing a cost per QALY at only a fraction of willingness to pay. These three bars assume a price per test of 400 Euro.

A sensitivity analysis using a price of 1000 Euro per test is illustrated in bar 4 and 5 for the same two risk groups and shows that at this price the cost per QALY is still in the range of willingness to pay.

Reference:
Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. The Swedish Institute for Health Economics. Ghatnekar O. et al. International Journal of Cancer, 2013.